Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Polyrizon Ltd. - Ordinary Shares (NQ:PLRZ)

12.45 -0.40 (-3.11%)
Streaming Delayed Price Updated: 10:13 AM EST, Feb 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Polyrizon Ltd. - Ordinary Shares

< Previous 1 2 Next >
News headline image
Polyrizon Signs an Agreement to Develop Intranasal Proprietary Non-Hallucinogenic Neuroplastogen Formulation
From Polyrizon Ltd.
Via GlobeNewswire
News headline image
Clearmind Medicine Enters into Development Agreement to Advance Intranasal Formulation for its Proprietary Non-Hallucinogenic Neuroplastogen MEAI
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Polyrizon Intends to Acquire 51% Stake in Global Private Aviation Company
From Polyrizon Ltd.
Via GlobeNewswire
News headline image
Polyrizon Advances Regulatory Path with Initiation of Usability Study Program for NASARIX™ Allergy Blocker
From Polyrizon Ltd.
Via GlobeNewswire
News headline image
Polyrizon to Explore Revenue-Generating Investment Opportunities in High-Growth Sectors, Leveraging Strong Cash Position and Debt-Free Balance Sheet
From Polyrizon Ltd.
Via GlobeNewswire
News headline image
Polyrizon Completes Branding Process for PL-14 Allergy Blocker with Brand Name NASARIX™
From Polyrizon Ltd.
Via GlobeNewswire
News headline image
Polyrizon Announces New Pre-Clinical Results: PL-14 Demonstrates Significant Allergen-Blocking Performance Compared to a Standard Comparator
From Polyrizon Ltd.
Via GlobeNewswire
News headline image
As Flu Surge Continues, Polyrizon's Nasal Spray Emerges as Potential Extra Shield Solution for Both Vaccinated and Unvaccinated
From Polyrizon Ltd.
Via GlobeNewswire
News headline image
Polyrizon to Explore Revenue-Generating Real Asset Opportunities, Leveraging Strong Cash Position and Debt-Free Balance Sheet
From Polyrizon Ltd.
Via GlobeNewswire
News headline image
Polyrizon Submits Pre-Request for Designation to FDA for PL-16 Viral Blocker Designed to Reduce the Exposure to Influenza and Cold Viruses
From Polyrizon Ltd.
Via GlobeNewswire
News headline image
Polyrizon Announces Promising Permeation Kinetics Supporting Advancement of Its Intranasal Naloxone Hydrogel Program
From Polyrizon Ltd.
Via GlobeNewswire
News headline image
Polyrizon Completes FDA Pre-Submission Meeting for PL-14 Allergy Blocker Nasal Spray
From Polyrizon Ltd.
Via GlobeNewswire
News headline image
Polyrizon (NASDAQ: PLRZ) Soars as Superior Mucoadhesion Naloxone Hydrogel Signals Stronger Real-World Opioid Overdose Reversal Potential
Via AB Newswire
Topics Artificial Intelligence Death
News headline image
From Lab to Global Impact: Polyrizon's Journey to Potentially Redefining Next-Generation Nasal Protection
From Polyrizon Ltd.
Via GlobeNewswire
News headline image
Polyrizon Reports Positive Mucoadhesion Results for Intranasal Naloxone Hydrogel Compared to Marketed Intranasal Naloxone product
From Polyrizon Ltd.
Via GlobeNewswire
News headline image
Polyrizon Announces Successful Completion of Key Manufacturing Upscaling Milestone for Its Nasal Spray Platform
From Polyrizon Ltd.
Via GlobeNewswire
News headline image
Polyrizon Demonstrates Reversible Broad-Spectrum Viral Blocking by Its Intranasal Barrier-Forming Formulation
From Polyrizon Ltd.
Via GlobeNewswire
News headline image
Polyrizon Announces Positive Pre-Clinical Results: PL-14 Demonstrates Encouraging Allergen-Blocking Efficacy
From Polyrizon Ltd.
Via GlobeNewswire
News headline image
Polyrizon Submits Pre-Sub Package to the FDA for PL-14 Allergy Blocker
From Polyrizon Ltd.
Via GlobeNewswire
News headline image
Polyrizon Reports Successful Intranasal Delivery of PL-14 Allergy Blocker in Latest Study
From Polyrizon Ltd.
Via GlobeNewswire
News headline image
Polyrizon Regains Compliance with Nasdaq Listing Requirements
From Polyrizon Ltd.
Via GlobeNewswire
News headline image
Peraso (NASDAQ: PRSO) The Future of mmWave Technology as Takeover Bid Underscores Surging Confidence – More Stocks Inside
Via AB Newswire
News headline image
Polyrizon Reports Successful Intranasal Delivery of PL-14 Allergy Blocker in Latest Study
From Polyrizon Ltd.
Via GlobeNewswire
News headline image
Polyrizon Retains Nasdaq Listing Following Hearings Panel
From Polyrizon Ltd.
Via GlobeNewswire
News headline image
Polyrizon Reports Promising Results Demonstrating Successful Internasal Delivery of its Innovative Hydrogel Formulation for CNS Therapeutics
From Polyrizon Ltd.
Via GlobeNewswire
News headline image
Polyrizon Announces Receipt of Nasdaq Delisting Notice
From Polyrizon Ltd.
Via GlobeNewswire
News headline image
Polyrizon Emerges with Positive Preclinical Data on Nasal Protection Platform
From Polyrizon Ltd.
Via GlobeNewswire
News headline image
Polyrizon Targets $3.15B Epilepsy Market with Preclinical Studies for Innovative Rescue Treatment
From Polyrizon Ltd.
Via GlobeNewswire
News headline image
Polyrizon Reports Successful Safety Study of a Formulation of PL-14 Allergy Blocker in Human Nasal Tissue Model
From Polyrizon Ltd.
Via GlobeNewswire
News headline image
Polyrizon Receives Nasdaq Notification Regarding Minimum Bid Requirements
From Polyrizon Ltd.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.